
    
      Screening Period (Up to Four Weeks) to confirm eligibility for the study which will be
      determined by Screening tests, physical examination/medical history and fulfillment of
      eligibility criteria including assessment of pain.

      Study Period (14 Weeks) Approximately 360 eligible male and female patients will receive
      double-blind treatment for 14 weeks. Patients will be randomized in a 1:1:1 ratio to
      treatment with EMA401 100 mg BID, 300 mg BID or placebo.

      Patients will attend the study site at the end of the Baseline visit and end of Weeks 1, 3,
      5, 7, 9, 11, 13, and 14 for on-study assessments.
    
  